title: Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.
abstract: Background/Abstract: PD-L1 has been an important target of cancer immunotherapy. We have showed that in human gastric cancer tissues, over-expression of PD-L1 was significantly associated with cancer progression and patients' postoperative prognoses. However, as of now, how PD-L1 regulates the biological function of gastric cancer cells still remains elusive.
  
  
  METHODS
  We constructed the stable PD-L1 knockdown expression gastric cancer cell lines by using RNAi method, and further investigated the changes of biological functions including cell viability, migration, invasion, cell cycle, apoptosis, tumorigenicity in vivo, and the cytotoxic sensitivity to CIK therapy, in contrast to the control cells.
  
  
  RESULTS
  In the current study, we demonstrated that the knockdown of PD-L1 expression in human gastric cancer cells could significantly suppress the cell proliferation, migration, invasion, apoptosis, cell cycle, tumorigenicity in vivo and the cytotoxic sensitivity to CIK therapy.
  
  
  CONCLUSIONS
  Our results indicate that PD-L1 contributes towards transformation and progression of human gastric cancer cells, and its intervention could prove to be an important therapeutic strategy against gastric cancer.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.forename: Lujun
authors.initials: L
authors.lastname: Chen
authors.forename: Yuqi
authors.initials: Y
authors.lastname: Xiong
authors.forename: Xiao
authors.initials: X
authors.lastname: Zheng
authors.forename: Quanqin
authors.initials: Q
authors.lastname: Xie
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhou
authors.forename: Liangrong
authors.initials: L
authors.lastname: Shi
authors.forename: Changping
authors.initials: C
authors.lastname: Wu
authors.forename: Jingting
authors.initials: J
authors.lastname: Jiang
authors.forename: Haitao
authors.initials: H
authors.lastname: Wang
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics / Q000276:immunology; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D002453:Cell Cycle / Q000235:genetics / Q000276:immunology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics / Q000276:immunology; D002470:Cell Survival / Q000235:genetics / Q000276:immunology; D055612:Cytokine-Induced Killer Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D015194:Diffusion Chambers, Culture; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D013274:Stomach Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*
chemical_list: D060890:B7-H1 Antigen; C423236:CD274 protein, human; C508594:IL2 protein, human; D007376:Interleukin-2; D034741:RNA, Small Interfering
keywords: Cancer progression; Gastric cancer; Immunohistochemistry; PD-L1; RNAi